Inosine monophosphate dehydrogenase activity depends on plasma concentrations of mycophenolic acid and its glucuronides in kidney transplant recipients

Clinica Chimica Acta

Volumn 409, Issue 1-2, 2009, Pages 56-61

  Mino, Yasuaki ^a,b   Naito, Takafumi ^a   Otsuka, Atsushi ^a   Ozono, Seiichiro ^a   Kagawa, Yoshiyuki ^b   Kawakami, Junichi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Erythrocytes; Inosine 5 monophosphate dehydrogenase; Kidney transplantation; Mycophenolic acid; Pharmacokinetics

Indexed keywords

ALBUMIN; AZATHIOPRINE; CREATININE; CYCLOSPORIN A; DRUG METABOLITE; GLUCURONIDE; INOSINATE DEHYDROGENASE; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNINE; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; AGE; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RECIPIENT;

ADULT; ERYTHROCYTES; FEMALE; GLUCURONIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 70349804432     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.08.016     Document Type: Article

References (34)

1. Crabtree G.W., and Henderson J.F. Rate-limiting steps in the interconversion of purine ribonucleotides in Ehrlich ascites tumor cells in vitro. Cancer Res 31 (1971) 985-991
2. Jackson R.C., Weber G., and Morris H.P. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 256 (1975) 331-333
3. Glander P., Hambach P., Braun K.P., et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 4 (2004) 2045-2051
4. Sanquer S., Maison P., Tomkiewicz C., et al. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation. Clin Pharmacol Ther 83 (2008) 328-335
5. Wang J., Yang J.W., Zeevi A., et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 83 (2008) 711-717
6. Wang J., Zeevi A., Webber S., et al. A novel variant L263F in human inosine 5′-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics 17 (2007) 283-290
7. Devyatko E., Dunkler D., Bohdjalian A., et al. Lymphocyte activation and correlation with IMPDH activity under therapy with mycophenolate mofetil. Clin Chim Acta 394 (2008) 67-71
8. Weimert N.A., Derotte M., Alloway R.R., Woodle E.S., and Vinks A.A. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit 29 (2007) 141-149
9. Staatz C.E., and Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46 (2007) 13-58
10. Jeong H., and Kaplan B. Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2 (2007) 184-191
11. Shipkova M., Armstrong V.W., Wieland E., et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 126 (1999) 1075-1082
12. Mino Y., Naito T., Otsuka A., et al. Cyclosporine concentration-dependent increase in concentration ratio of mycophenolic acid acyl and phenol glucuronides to mycophenolic acid in stable kidney transplant recipients. Clin Biochem 42 (2009) 595-601
13. Mino Y., Naito T., Matsushita T., et al. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. Ther Drug Monit 30 (2008) 656-661
14. Mourad M., Malaise J., Chaib Eddour D., et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 47 (2001) 1241-1248
15. Pillans P.I., Rigby R.J., Kubler P., et al. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem 34 (2001) 77-81
16. Pawinski T., Durlik M., Szlaska I., Urbanowicz A., Majchrnak J., and Gralak B. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. J Clin Pharm Ther 31 (2006) 27-34
17. Sintchak M.D., Fleming M.A., Futer O., et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 85 (1996) 921-930
18. Schütz E., Shipkova M., Armstrong V.W., Wieland E., and Oellerich M. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 45 (1999) 419-422
19. Vethe N.T., Bremer S., Rootwelt H., and Bergan S. Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. Ther Drug Monit 30 (2008) 647-655
20. Sugitani A., Kitada H., Ota M., et al. Revival of effective and safe high-dose mizoribine for the kidney transplantation. Clin Transplant 20 (2006) 590-595
21. Kuypers D.R. Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome. Transpl Int 18 (2005) 140-150
22. Kusumi T., Tsuda M., Katsunuma T., and Yamamura M. Dual inhibitory effect of bredinin. Cell Biochem Funct 7 (1989) 201-204
23. Sanquer S., Breil M., Baron C., Dhamane D., Astier A., and Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 65 (1999) 640-648
24. Weigel G., Griesmacher A., Zuckermann A.O., Laufer G., and Mueller M.M. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. Clin Pharmacol Ther 69 (2001) 137-144
25. Vethe N.T., Mandla R., Line P.D., Midtvedt K., Hartmann A., and Bergan S. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment. Scand J Clin Lab Invest 66 (2006) 31-44
26. Glander P., Hambach P., Braun K.P., et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther 41 (2003) 470-476
27. Weber L.T., Shipkova M., Armstrong V.W., et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13 (2002) 759-768
28. Cattaneo D., Gaspari F., Ferrari S., et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 15 (2001) 402-409
29. Mino Y., Naito T., Matsushita T., Kagawa Y., and Kawakami J. Simultaneous determination of mycophenolic acid and its glucuronides in human plasma using isocratic ion pair high-performance liquid chromatography. J Pharm Biomed Anal 46 (2008) 603-608
30. Bremer S., Vethe N.T., Rootwelt H., and Bergan S. Expression of IMPDH1 is regulated in response to mycophenolate concentration. Int Immunopharmacol 9 (2009) 173-180
31. Nowak I., and Shaw L.M. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 41 (1995) 1011-1017
32. Glander P., Braun K.P., Hambach P., et al. Non-radioactive determination of inosine 5′-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem 34 (2001) 543-549
33. Vethe N.T., and Bergan S. Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy. Ther Drug Monit 28 (2006) 608-613
34. Stypinski D., Obaidi M., Combs M., Weber M., Stewart A.J., and Ishikawa H. Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Br J Clin Pharmacol 63 (2007) 459-468